490 related articles for article (PubMed ID: 16678077)
1. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
[TBL] [Abstract][Full Text] [Related]
2. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
3. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Price S; Langholff W; Londhe A; Sandborn WJ
Am J Gastroenterol; 2012 Sep; 107(9):1409-22. PubMed ID: 22890223
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
Lichtenstein GR; Olson A; Travers S; Diamond RH; Chen DM; Pritchard ML; Feagan BG; Cohen RD; Salzberg BA; Hanauer SB; Sandborn WJ
Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
[TBL] [Abstract][Full Text] [Related]
5. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Langholff W; Londhe A; Sandborn WJ
Am J Gastroenterol; 2014 Feb; 109(2):212-23. PubMed ID: 24394749
[TBL] [Abstract][Full Text] [Related]
6. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
7. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
[TBL] [Abstract][Full Text] [Related]
8. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
[TBL] [Abstract][Full Text] [Related]
9. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
10. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
Lémann M; Mary JY; Duclos B; Veyrac M; Dupas JL; Delchier JC; Laharie D; Moreau J; Cadiot G; Picon L; Bourreille A; Sobahni I; Colombel JF;
Gastroenterology; 2006 Apr; 130(4):1054-61. PubMed ID: 16618399
[TBL] [Abstract][Full Text] [Related]
11. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
[TBL] [Abstract][Full Text] [Related]
13. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
Marchal L; D'Haens G; Van Assche G; Vermeire S; Noman M; Ferrante M; Hiele M; Bueno De Mesquita M; D'Hoore A; Penninckx F; Rutgeerts P
Aliment Pharmacol Ther; 2004 Apr; 19(7):749-54. PubMed ID: 15043515
[TBL] [Abstract][Full Text] [Related]
14. Mortality and cause of death in Japanese patients with Crohn's disease.
Uno H; Yao T; Matsui T; Sakurai T; Iida M; Matsumoto T; Aoyagi K; Fuchigami T
Dis Colon Rectum; 2003 Oct; 46(10 Suppl):S15-21. PubMed ID: 14530654
[TBL] [Abstract][Full Text] [Related]
15. Safety of infliximab in 10 years of clinical practice.
O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA
Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689
[TBL] [Abstract][Full Text] [Related]
16. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence.
Ferrante M; de Hertogh G; Hlavaty T; D'Haens G; Penninckx F; D'Hoore A; Vermeire S; Rutgeerts P; Geboes K; van Assche G
Gastroenterology; 2006 May; 130(6):1595-606. PubMed ID: 16697723
[TBL] [Abstract][Full Text] [Related]
17. Risks and benefits of infliximab for the treatment of Crohn's disease.
Siegel CA; Hur C; Korzenik JR; Gazelle GS; Sands BE
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1017-24; quiz 976. PubMed ID: 16843733
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
19. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms.
Pfefferkorn M; Burke G; Griffiths A; Markowitz J; Rosh J; Mack D; Otley A; Kugathasan S; Evans J; Bousvaros A; Moyer MS; Wyllie R; Oliva-Hemker M; Carvalho R; Crandall W; Keljo D; Walters TD; LeLeiko N; Hyams J
J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):168-74. PubMed ID: 19179878
[TBL] [Abstract][Full Text] [Related]
20. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
